Search by drug, manufacturer, or indication

Displaying 651 - 660 of 1165

Xultophy (insulin degludec/liraglutide)

Status:

Concluded without agreement

Manufacturer:

Novo Nordisk Canada Inc.

Indication:

Diabetes Mellitus, Type 2

Last updated April 26, 2021

Inclunox (enoxaparin)

Status:

Concluded with an LOI

Manufacturer:

Sandoz Canada Inc.

Indication:

Deep vein thrombosis (treatment and prevention)

Last updated April 15, 2021

Nyvepria (pegfilgrastim)

Status:

Concluded with an LOI

Manufacturer:

Pfizer Canada ULC

Indication:

Febrile neutropenia in non-myeloid malignancies

Last updated April 5, 2021

Redesca (enoxaparin)

Status:

Concluded with an LOI

Manufacturer:

Valeo Pharma Inc.

Indication:

Deep-Vein Thrombosis (treatment), without Symptomatic Pulmonary Embolism

Last updated March 24, 2021

Taltz (ixekizumab)

Status:

Concluded without agreement

Manufacturer:

Eli Lilly Canada Inc.

Indication:

Ankylosing spondylitis

Last updated March 19, 2021

Otezla (apremilast)

Status:

Concluded without agreement

Manufacturer:

Amgen Canada Inc.

Indication:

Psoriatic Arthritis

Last updated March 17, 2021

Otezla (apremilast)

Status:

Concluded without agreement

Manufacturer:

Amgen Canada Inc.

Indication:

Psoriasis, moderate to severe plaque

Last updated March 17, 2021

Xospata (Gilteritinib)

Status:

Concluded with an LOI

Manufacturer:

Astellas Pharma Inc.

Indication:

Acute Myeloid Leukemia (AML)

Last updated March 15, 2021

Blood glucose test strips (blood glucose test strips)

Status:

Concluded with an LOI

Manufacturer:

Skymed Monitors Inc.

Indication:

Diabetes Mellitus, Type 1 & 2

Last updated February 26, 2021

Dupixent (dupilumab)

Status:

Concluded with an LOI

Manufacturer:

Sanofi Genzyme Canada

Indication:

Atopic dermatitis

Last updated February 25, 2021